Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc.
Related news for (SNY)
- From EV Acceleration to SaaS Breakouts: Wall Street’s Thursday Focus
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/04/25 06:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/04/25 05:00 AM
- Strategic Pivots, Scientific Breakthroughs, and Tech-fueled Optimism
- Breaking News: MoBot’s Latest Update as of 09/03/25 06:00 AM